Cytokinetics Inc. has a new partner in Greater China for its potential heart failure drug aficamten ahead of what could be a flurry of possible deals around the expected multibillion-dollar drug.
The researchers hope the breakthrough will help scientists cure a genetic disorder that increases the likelihood of dying from coronary artery disease at a young age.